The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Prior to the availability of the recombinant vaccine in 2004, the only equine WNV vaccine available on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the question could be posed as to whether a single dose of the recombinant vaccine would be effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. In this study we demonstrate that vaccination of horses with a canarypox-vectored recombinant vaccine, under field conditions, results in a marked anamnestic response in horses previously vaccinated with an inactivated WNV vaccine.
Grosenbaugh
D A
DA
Merial Limited, 115 Transtech Drive, Athens, GA, 30601, USA.
Backus
C S
CS
Karaca
K
K
Minke
J M
JM
Nordgren
R M
RM
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D028121:Canarypox virus / Q000235:genetics; D005260:Female; D006734:Horse Diseases / Q000517:prevention & control*; D006736:Horses; D008297:Male; D011897:Random Allocation; D015164:Vaccines, Inactivated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia / Q000662:veterinary; D014901:West Nile Fever / Q000517:prevention & control / Q000662:veterinary*; D014902:West Nile virus / Q000276:immunology*
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines